Table 3.
Treatment factors of transarterial chemoembolization (patients, N = 35) (total DEB-TACE, N = 66)
| TACE intervention timing (n = 35) | |
| 1st line therapy failure | 19 (54.3%) |
| 2nd line therapy failure | 10 (28.5%) |
| 3rd line therapy failure | 5 (14.3%) |
| 4th line therapy failure | 1 (2.9%) |
| No. of liver metastasis (n = 35) | |
| 1 | 6 (17.1%) |
| 2 | 2 (5.7%) |
| 4 | 1 (2.9%) |
| ≧5 | 26 (74.3%) |
| Location of liver metastasis (n = 35) | |
| Right lobe | 10 (28.6%) |
| Left lobe | 0 (0%) |
| Both lobes | 25 (71.4%) |
| Tumor burden of liver (n = 35) | |
| 10 ~ 30% | 19 (54.3%) |
| 30 ~ 50% | 10 (28.6%) |
| 50 ~ 70% | 6 (17.1%) |
| Number of DEB-TACE courses (n = 35) | |
| 1 | 19 (54.3%) |
| 2 | 8 (22.8%) |
| 3 | 4 (11.4%) |
| 4 | 1 (2.9%) |
| 5 | 3 (8.6%) |
| Median | 1 |
| Total embolization numbers | 66 |
| DEB-TACE agent (n = 66) | |
| Irinotecan | 60 (90.9%) |
| Epirubicin | 6 (9.1%) |
| Best response (n = 35) | |
| Partial response (PR) | 5 (14.3%) |
| Stable disease (SD) | 14 (40.0%) |
| Progressive disease (PD) | 13 (37.1%) |
| Not availablea | 3 (8.6%) |
| Disease control rate (PR + SD) | 19 (54.3%) |
aOne patient died 2 months later after the first DEB-TACE due to intra-abdominal infection and gastrointestinal bleeding. Two patient lost follow-up after the first DEB-TACE